Literature DB >> 30990381

Gadoxetic Acid-enhanced MRI of Hepatocellular Carcinoma: Value of Washout in Transitional and Hepatobiliary Phases.

Dong Hwan Kim1, Sang Hyun Choi1, So Yeon Kim1, Min-Ju Kim1, Seung Soo Lee1, Jae Ho Byun1.   

Abstract

Background Current Liver Imaging Reporting and Data System guidelines define the washout appearance of gadoxetic acid-enhanced MRI only during the portal venous phase. Defining washout only during the portal venous phase may lead to lower sensitivity for diagnosis of hepatocellular carcinoma (HCC). Purpose To compare the diagnostic performances of three gadoxetic acid-enhanced MRI criteria for HCC according to the phases during which washout appearance was determined. Materials and Methods In this retrospective study, patients with a hepatic nodule detected at US surveillance for HCC from January to December 2012 underwent gadoxetic acid-enhanced MRI. Three diagnostic MRI criteria for HCC were defined according to the phases during which washout appearance was observed, with the presence of arterial phase hyperenhancement and hypointensity noted (a) only during the portal venous phase, with washout confined to the portal venous phase; (b) during the portal venous phase or transitional phase, with washout extended to the transitional phase; or (c) during the portal venous, transitional, or hepatobiliary phase, with washout extended to the hepatobiliary phase. If a nodule showed marked T2 hyperintensity or a targetoid appearance, it was precluded from the diagnosis of HCC. The sensitivity and specificity were compared by using a generalized estimating equation. Results A total of 178 patients were included (mean age ± standard deviation, 55.3 years ± 9.1) with 203 surgically confirmed hepatic nodules (186 HCCs and 17 non-HCCs) measuring 3.0 cm or smaller. The sensitivity with washout extended to the hepatobiliary phase (95.2% [177 of 186]) was better than that with washout extended to the transitional phase (90.9% [169 of 186]; P = .01) and washout confined to the portal venous phase (75.3% [140 of 186]; P < .01). The specificity with extensions of washout to the transitional phase and hepatobiliary phase (82% [14 of 17] for both) was similar to that obtained with washout confined to the portal venous phase (94.1% [16 of 17]) (P = .47). Conclusion After exclusion of typical hemangiomas and nodules with a targetoid appearance, extending washout appearance to the transitional or hepatobiliary phase (instead of restricting it to the portal venous phase) allowed higher sensitivity without a reduction in specificity. © RSNA, 2019 See also the editorial by Fowler and Sirlin in this issue.

Entities:  

Year:  2019        PMID: 30990381     DOI: 10.1148/radiol.2019182587

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

Review 1.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

2.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.

Authors:  Jingbiao Chen; Sichi Kuang; Yao Zhang; Wenjie Tang; Sidong Xie; Linqi Zhang; Dailin Rong; Bingjun He; Ying Deng; Yuanqiang Xiao; Wenqi Shi; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-10-11

Review 3.  LI-RADS and transplantation: challenges and controversies.

Authors:  Guilherme M Cunha; Dorathy E Tamayo-Murillo; Kathryn J Fowler
Journal:  Abdom Radiol (NY)       Date:  2021-01

4.  Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.

Authors:  Jielin Pan; Wenjuan Li; Lingjing Gu; Chaoran Liu; Ke Zhang; Guobin Hong
Journal:  Eur Radiol       Date:  2022-05-17       Impact factor: 5.315

5.  Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?

Authors:  Sidong Xie; Yao Zhang; Jingbiao Chen; Ting Jiang; Weimin Liu; Dailin Rong; Lin Sun; Linqi Zhang; Bingjun He; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2021-11-13

6.  Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.

Authors:  Sang Min Lee; Jeong Min Lee; Su Joa Ahn; Hyo Jin Kang; Hyun Kyung Yang; Jeong Hee Yoon
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

Review 7.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

8.  Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.

Authors:  Sunyoung Lee; Seung-Seob Kim; Dong Ryul Chang; Hyerim Kim; Myeong-Jin Kim
Journal:  Clin Mol Hepatol       Date:  2020-06-04

Review 9.  Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.

Authors:  Tae Hyung Kim; Haeryoung Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

10.  Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma.

Authors:  Yueming Li; Jianwei Chen; Shuping Weng; Chuan Yan; Rongping Ye; Yuemin Zhu; Liting Wen; Dairong Cao; Jinsheng Hong
Journal:  Ann Transl Med       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.